Part
01
of two
Part
01
Chemotherapy-induced Peripheral Neuropathy - Part One
The main cause of Chemotherapy-induced Peripheral Neuropathy (CIPN) is adverse effects that occur because of the use of chemotherapy drugs. This may last for years even after termination of chemotherapy. Approximately 48% of cancer patients who receive chemotherapy are diagnosed with Chemotherapy-induced Peripheral Neuropathy (CIPN).
After conducting an in-depth search through various cancer and chemotherapy sites such as UCSF Health.org, Cancer.net, Cancer.org, Medical News Today, Mayo Clinic, Clinical Trials.gov, and Peripheral Neuropathy research article, we have established that the information on demographic statistics specifically on age, gender, and ethnicity, and the disease history for Chemotherapy-induced Peripheral Neuropathy (CIPN) is not available publicly. Below we have discussed our research methodology including how we searched and why some of the required information is not available publicly.
METHODOLOGY
Initially, our research team searched for information on the epidemiology, demographic statistics, and disease history of Chemotherapy-induced Peripheral Neuropathy (CIPN) and could locate the information on the causality of Chemotherapy-induced Peripheral Neuropathy (CIPN) precompiled through credible sources. However, the information on epidemiology, demographic statistics, and disease history was very limited in the public domain. The research was conducted through reports and articles obtained from Chemotherapy-induced Peripheral Neuropathy institutes, cancer organizations, healthcare articles such as cancer.org, ASCO Pubs, Medscape, NCBI, cancer.gov, US census, and others. Most of the information we found was related to the clinical trials of drugs induced for CIPN.
Later, we searched CIPN market reports through various business articles and pharma company publications to find the information on epidemiology in various sites such as Global NewsWire, PR NewsWire, MarketWatch, Abbott, Pfizer, GSK, and others. Through this search, we were able to locate one of the reports published by Global NewsWire which revealed that in 2016, there were 100,000 to 300,000 Chemotherapy-induced Peripheral Neuropathy patients and the incidence rate (or growth rate) is at 0.35% (CAGR). So, we used this data and calculated the prevalence of CIPN patients for 2018.
As there was no direct information on the incidence, and the prevalence of CIPN we have provided the above statistics as an approximate value.
Information on demographic statistics and disease history of Chemotherapy-induced Peripheral Neuropathy was not available due to the reason that unlike other diseases CIPN is not common for all population and very specific for patients with chemotherapy. So, the research is very niche to derive further segmentation by age, gender, ethnicity, and history. This might be the reason no research reports, survey articles, news articles, or other media articles have not mentioned this information anywhere. Below are the strategies we applied to search the required data:
Based on Initial search, we could conclude that this disease is not common for all population and very specific for patients with chemotherapy. So, we tried to locate the statistics on the number of patients who received chemotherapy by age, gender, ethnicity and could locate recent cancer statistics by gender which did not show much variation by gender. So, we could not identify any insights on statistics of chemotherapy while searching through various cancer and chemotherapy sites such as UCSF Health.org, Cancer.net, Cancer.org, Medical News Today, Mayo Clinic, Clinical Trials.gov, and others.
Further, we tried to derive the segmentation or classification of Chemotherapy-induced Peripheral Neuropathy (CIPN) by age, gender, ethnicity from Peripheral Neuropathy research articles and could locate most of the information on Diabetic peripheral neuropathy and Peripheral Neuropathy in general. But no further segmentation details were found while searching through Cleveland Clinic Med, DMS Journal, AAFP, BMJ, NCBI, ASCO Pubs, etc.
Then, we expanded the scope of our research beyond the standard timeline of 24 months as details on demographic statistics, and disease history of Chemotherapy-induced Peripheral Neuropathy may be varied minimally by the timeline. However, through this strategy also, we could only locate information on treatment, diagnosis etc. but nothing specific to age, gender, ethnicity and history while searching through various websites such as US Census, WHO, Clinical Trials.gov, NCBI, PJIAP, Semantic Scholar, ASCO, WCRF, Cancer.gov, Medicalxpress, Online Library Wiley, etc.
After conducting an in-depth search through the above-mentioned strategy, we have established that the information on demographic statistics and disease history of Chemotherapy-induced Peripheral Neuropathy are not available publicly.
Chemotherapy-induced Peripheral Neuropathy (CIPN)
1. EPIDEMIOLOGY
Incidence: There were 100,000 to 300,000 Chemotherapy-induced Peripheral Neuropathy patients in 2016 and the incidence rate (or growth rate) was 0.35% (CAGR).
Therefore, average CIPN cases in 2016 can be calculated as 200,000 (100,000 + 300,000/2) and the growth rate (CAGR) is 0.35%. Using an online calculator, we have calculated the number of CIPN patients in the US to be 201,402 in 2018.
Prevalence: The rate of prevalence in CIPN patients varies as follows:
Approximately, 48% of cancer patients who receive chemotherapy are diagnosed with Chemotherapy-induced Peripheral Neuropathy.
DEMOGRAPHIC STATISTICS
Based on our research, we have established that the information on demographic statistics specifically on age, gender, and ethnicity for CIPN patients is not available publicly. However, our research concluded that there is no significant difference in the incidence and prevalence of chemotherapy-induced peripheral neuropathy in women with chemotherapy-induced peripheral neuropathy by race or ethnicity or poverty.
DISEASE HISTORY/CAUSALITY
Causality: The main cause of Chemotherapy-induced Peripheral Neuropathy (CIPN) is the adverse effect caused by drugs which are used during chemotherapy and this may last for years even after termination of chemotherapy.